Caxton Associates LP Sells 3,284 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Caxton Associates LP lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,402 shares of the biotechnology company's stock after selling 3,284 shares during the period. Caxton Associates LP's holdings in United Therapeutics were worth $495,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the fourth quarter worth about $25,000. Millstone Evans Group LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the last quarter. Natixis bought a new position in United Therapeutics during the 4th quarter valued at approximately $85,000. Finally, Anchor Investment Management LLC raised its stake in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after buying an additional 30 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on UTHR. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday. Morgan Stanley raised their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Finally, UBS Group upped their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $392.00.

Insider Activity

In other United Therapeutics news, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the sale, the director now owns 1,750 shares in the company, valued at approximately $497,962.50. This trade represents a 69.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 75,500 shares of company stock valued at $24,245,880 in the last 90 days. Company insiders own 11.90% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR opened at $295.02 on Wednesday. United Therapeutics Co. has a one year low of $260.41 and a one year high of $417.82. The business has a fifty day moving average of $300.98 and a 200 day moving average of $343.30. The firm has a market capitalization of $13.30 billion, a P/E ratio of 12.96, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same period in the previous year, the company posted $6.17 EPS. The business's quarterly revenue was up 17.2% compared to the same quarter last year. Analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.